1) Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol, 35, 721-741 (1997).
2) 友田 吉則, 福本 真理子. 解毒薬 活性炭. 中毒研究, 31, 41-46 (2018).
3) 日本薬局方第 17 改正 解説書 医薬品各条 薬用炭. ppC5616-C5620 (2016).
4) 荒 鶴雄. 活性炭素 改版, 丸善, 東京 (1932).
5) Cooney DO. Activated charcoal in medical applications, Marcel Dekker, New York, (1995).
6) 織 孝, 江口 良友. 活性炭 -効果的な応用への手引き- 第 3 版, 共立出版, 東京 (1976).
7) 阿部 郁夫. 炭の製造と利用技術 多孔質炭素の広がる用途, エヌティーエス, 東京(2009).
8) Raphael von Ostrejko, Father of activated carbon https://speicyte.wixsite.com/raphael-von-ostrejko (閲覧日 2021 年 1 月 5 日)
9) Troy DB. Remington : the science and practice of pharmacy. 21ed., Lippincott , Philadelphia (2006).
10) 林 昌彦, 川下 由加. 活性炭ハンドブック 構造制御とキャラクタリゼーション, 丸善, 東京 (2011).
11) Lapus RM. Activated charcoal for pediatric poisonings: the universal antidote? Curr Opin Pediatr, 19, 216-222 (2007).
12) Greene S, Harris C, Singer J. Gastrointestinal decontamination of the poisoned patient. Pediatr Emerg Care, 24, 176-186; quiz 187-179 (2008).
13) 落合 陽. 経口吸着剤の併用. ICU と CCU, 9, 959-967 (1985).
14) Historical production and use of carbon materials. http://www.caer.uky.edu/carbon/history/carbonhistory.shtml. (閲覧日 2018 年 10 月3 日)
15) Hort. Schmidts Jahrebuher, 4, 149 (1834).
16) Garrod AB. On purified animal charcoal as an antidote to all vegetable and some mineral poisons. Tr. M .Soc. London, 1, 195 (1846).
17) Graham T, Hoffmann AW. Report upon the alleged adulteration of pale ales by strychinine. Quarterly Journal of the Chemical Society of London, 5, 173 (1853).
18) Andersen AH. Experimental studies on the pharmacology of activated charcoal; adsorption power of charcoal in aqueous solutions. Acta Pharmacol Toxicol (Copenh), 2, 69-78 (1946).
19) Holt LE, Holz DH. The black bottle. A consideration of the role of Charcoal in the treatment of poisoning in children. J Pediatr, 63, 306-314 (1963).
20) The United States pharmacopeia, Activated Charcoal. USP, pp. 967 (1965).
21) The United States pharmacopeia, Activated Charcoal. USP, pp. 104-105 (1970).
22) United States pharmacopeia dispensing information. U. S. Pharmacopeial Convention. pp169-170 (1981).
23) European Pharmacopoeia volumeⅠ. Carbon, activated. activated charcoal, pp144 (1969).
24) British Pharmacopoeia 1973 Addendum 1978., Pharmaceutical Press, London, pp. 19 (1978).
25) 日本薬局方 第五改正, 薬業時報社, 東京, (1932).
26) Dreisbach RH. Handbook of poisoning. Diagnosis treatment. 7th., Lange Medical Publications,, CA (1971).
27) Dordoni B, Willson RA, Thompson RP, Williams R. Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J, 3, 86-87 (1973).
28) Lawrence FH, McGrew WR. Activated charcoal: a forgotten antidote. J Maine Med Assoc, 66, 311-313 (1975).
29) Activated charcoal in the treatment of acute poisoning. Drug Ther Bull, 12, 27-28 (1974).
30) Levy G, Gwilt PR. Activated charcoal for acute acetaminophen intoxication. Jama, 219, 621 (1972).
31) Levy G, Houston JB. Effect of activated charcoal on acetaminophen absorption.Pediatrics, 58, 432-435 (1976).
32) Comstock EG. Guide to management of drug overdose. Clin Toxicol, 8, 475-482 (1975).
33) Chin L, Picchioni AL, Bourn WM, Laird HE. Optimal antidotal dose of activated charcoal. Toxicol Appl Pharmacol, 26, 103-108 (1973).
34) Levy G, Tsuchiya T. Effect of activated charcoal on aspirin absorption in man. Part I. Clin Pharmacol Ther, 13, 317-322 (1972).
35) Chin L, Picchioni AL, Duplisse BR. The action of activated charcoal on poisons in the digestive tract. Toxicol Appl Pharmacol, 16, 786-799 (1970).
36) Olkkola KT. Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man. Br J Clin Pharmacol, 19, 767-773 (1985).
37) Neuvonen PJ, Olkkola KT. Effect of dose of charcoal on the absorption of disopyramide, indomethacin and trimethoprim by man. Eur J Clin Pharmacol, 26, 761-767 (1984).
38) Chyka PA, Seger D, Krenzelok EP, Vale JA, American Academy of Clinical T, European Association of Poisons C, Clinical T. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila), 43, 61-87 (2005).
39) 浅利 靖. 消化管除染 活性炭. 日本中毒学会編, 急性中毒標準診療ガイド, じほう, 東京, pp. 26-29, 32-38 (2008).
40) 日本薬学会. 衛生試験法・注解, 金原出版, 東京 (2015).
41) 福井 昭, 平山 晃, 野原 基. 2-Ethyl-1, 3-Hexanediol キレート抽出法およびプロトン化クルクミンを用いる食品中のホウ酸の定量化. 衛生化学, 29, 323-328 (1983).
42) Langmuir I. The Adsorption of Gases on Plane Surfaces of Glass, Mica and Platinum. J. Am. Chem. Soc., 40, 1361-1403 (1918).
43) Joachimoglu G. Adsorption capacity of animal charcoal and its determination.Biochem. Z, 77, 1-13 (1916).
44) Joachimoglu G. The theoretical principles of charcoal therapy. Chem-Zig, 44, 780 (1920).
45) Joachimoglu G. Adsroption and detoxification power of certain charcoals. Biochem Z, 134, 493-499 (1923).
46) Keeser E. Adsorption and the distribution of drugs in the organism. Ⅲ. Biochem Z, 144, 536-544 (1924).
47) Hörst F. The adsorption capacity of various charcoals. . Biochem.Z, 113, 99-110 (1921).
48) Koenig F. Evaluation of charbo medicinalis. Pharm. Zentralhalle, 64, 205 (1923).
49) Koenig F. Adsorption value of charbo medicinalis. Pharm. Zentralhalle, 66, 645 (1925).
50) Merck E. Estimation of adsorptive power of Carbo medicinalis. Pharm. Ztg. , 69, 523-524 (1924).
51) Rohmann C, Gericke P. Evaluation of medicinal carbons. . Pharm. Ztg., 77, 652-655 (1932).
52) Bari Z. Evaluation of medicinal charcoals and certain charcoal preparations.Pharm. Ztg. , 78, 284-288 (1933).
53) Hofmann H, Neubauer M. Medicinal charcoal and the differences in adsorption capacity of various charcoal preparations. Pharmazie, 3, 529-531 (1948).
54) Charonnat R, Leclerc J. Determination of the adsorbing power of activated charcoal. Ann. Pharm. Franc., 7, 625-627 (1949).
55) Sjogren B, Wallden E. The adsorbing power of medicinal charcoal. Svensk. Farm. Tid., 39, 617-620 (1935).
56) Sing KSW, Everett DH, Haul RAW, Moscou L, A. PR, Rouquerol J, Siemienewska T.Reporting physisorption data for gas/solid systems with Special Reference to the Determination of Surface Area and Porosity. Pure Appl. Chem., 57, 603-619 (1985).
57) 遠藤 容子, 波多野 弥生. 最近のトピックス カフェイン中毒 わが国におけるカフェイン中毒 含有製品と発生状況の現状. 中毒研究, 29, 347-353 (2016).
58) Theobald J, Schneider J, Cheema N, DesLauriers C. Time to development of metformin-associated lactic acidosis. Clin Toxicol (Phila), 58, 758-762 (2020).
59) 小笠原 舞, 藤野 修, 浅井 真理子, 小野 京香, 西澤 欣子, 水入 苑生, 重本 憲一郎, 正木 崇生. ブロム酸塩を主成分とするパーマ液の誤飲により急性腎障害を発症し、点滴のみで腎機能が改善しえた1例. 中国腎不全研究会誌, 25, 11-12 (2017).
60) 森山 太揮, 澤野 宏隆, 塚本 菜穂, 三浦 拓郎, 林 靖之. ブロム酸塩中毒により急性腎不全と高度難聴をきたした1例. 中毒研究, 32, 223 (2019).
61) Nakamura T, Kawasaki N, Matsumoto K, Tanada S. Effect of Particle Size on the Adsorption of Theophylline onto Activated Charcoal, In Vitro Study. 中毒研究, 16, 57-62 (2003).
62) Hoegberg LC, Angelo HR, Christophersen AB, Christensen HR. Effect of ethanol and pH on the adsorption of acetaminophen (paracetamol) to high surface activated charcoal, in vitro studies. J Toxicol Clin Toxicol, 40, 59-67 (2002).
63) Bainbridge CA, Kelly EL, Walking WD. In vitro adsorption of acetaminophen onto activated charcoal. J Pharm Sci, 66, 480-483 (1977).
64) Favin FD, Klein-Schwartz W, Oderda GM, Rose SR. In vitro study of lithium carbonate adsorption by activated charcoal. J Toxicol Clin Toxicol, 26, 443-450 (1988).
65) Welch DW, Johnson PN, Driscoll JL, Lewander WJ. In vitro potassium binding : a comparison of activated charcoal and sodium polystyrene sulfonate. Vet Hum Toxicol, 28, 495 (1986).
66) Oderda GM, Klein-Schwartz W, Insley BM. In vitro study of boric acid and activated charcoal. J Toxicol Clin Toxicol, 25, 13-19 (1987).
67) Hoffman RS, Stringer JA, Feinberg RS, Goldfrank LR. Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate. J Toxicol Clin Toxicol, 37, 833-837 (1999).
68) Edwards KD, McCredie M. Studies on the binding properties of acidic, basic and neutral drugs to anion and cation exchange resins and charcoal in vitro. Med J Aust, 1, 534-539 (1967).
69) Decker WJ, Combs HF, Corby DG. Adsorption of drugs and poisons by activated charcoal. Toxicol Appl Pharmacol, 13, 454-460 (1968).
70) Gomez HF, McClafferty HH, Flory D, Brent J, Dart RC. Prevention of gastrointestinal iron absorption by chelation from an orally administered premixed deferoxamine/charcoal slurry. Ann Emerg Med, 30, 587-592 (1997).
71) Corby DG, Decker WJ. Management of acute poisoning with activated charcoal.Pediatrics, 54, 324-329 (1974).
72) Andersen AH. Experimental studies on the pharmacology of activated charcoal; the effect of pH on the adsorption by charcoal from aqueous solutions. Acta Pharmacol Toxicol (Copenh), 3, 119-218 (1947).
73) 日本工業規格. JIS7260-117 分配係数 (1-オクタノール/水)の測定 (2006).
74) Minocha A, Herold DA, Barth JT, Gideon DA, Spyker DA. Activated charcoal in oral ethanol absorption: lack of effect in humans. J Toxicol Clin Toxicol, 24, 225-234 (1986).
75) Olkkola KT. Does ethanol modify antidotal efficacy of oral activated charcoal studies in vitro and in experimental animals. J Toxicol Clin Toxicol, 22, 425-432 (1984).
76) North DS, Thompson JD, Peterson CD. Effect of activated charcoal on ethanol blood levels in dogs. Am J Hosp Pharm, 38, 864-866 (1981).
77) Neuvonen PJ, Olkkola KT. Activated charcoal and syrup of ipecac in prevention of cimetidine and pindolol absorption in man after administration of metoclopramide as an antiemetic agent. J Toxicol Clin Toxicol, 22, 103-114 (1984).
78) Neuvonen PJ, Olkkola KT. Effect of purgatives on antidotal efficacy of oral activated charcoal. Hum Toxicol, 5, 255-263 (1986).
79) Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics, 55, 871-876 (1975).
80) Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis, 11, 525-548, vi (2007).
81) Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of Oral N- Acetylcysteine in the Treatment of Acetaminophen Overdose - Analysis of the National Multicenter Study (1976 to 1985). New Engl J Med, 319, 1557-1562 (1988).
82) Rumack BH, Peterson RG. Acetaminophen overdose: incidence, diagnosis, and management in 416 patients. Pediatrics, 62, 898-903 (1978).
83) あゆみ製薬. アセチルシステイン内用液 17.6%％「あゆみ」添付文書 (2016 年 1 月).
84) Orisakwe OE, Afonne OJ, Ilondu NA, Obi E, Ufearo CS, Agbasi PU, Maduka SO, Orish CN, Orish VN. Influence of prokinetics on the gastrointestinal transit and residence times of activated charcoal. J Pak Med Assoc, 52, 354-356 (2002).
85) Hayashi M, Okunaga K, Nishida S, Kawamura K, Eda K. Oxidative transformation of thiols to disulfides promoted by activated carbon-air system. Tetrahedron Lett, 51, 6734-6736 (2010).
86) Pereira MFR, Orfao JJM, Figueiredo JL. Oxidative dehydrogenation of ethylbenzene on activated carbon catalysts. I. Influence of surface chemical groups. Appl Catal a-Gen, 184, 153-160 (1999).
87) Chinouth RW, Czajka PA, Peterson RG. N-acetylcysteine adsorption by activated charcoal. Vet Hum Toxicol, 22, 392-394 (1980).
88) Rybolt TR, Burrell DE, Shults JM, Kelley AK. In vitro coadsorption of acetaminophen and N-acetylcysteine onto activated carbon powder. J Pharm Sci, 75, 904-906 (1986).
89) Klein-Schwartz W, Oderda GM. Adsorption of oral antidotes for acetaminophen poisoning (methionine and n-acetylcysteine) by activated charcoal. Clin Toxicol, 18, 283-290 (1981).
90) Ekins BR, Ford DC, Thompson MI, Bridges RR, Rollins DE, Jenkins RD. The effect of activated charcoal on N-acetylcysteine absorption in normal subjects. Am J Emerg Med, 5, 483-487 (1987).
91) Chamberlain JM, Gorman RL, Oderda GM, Klein-Schwartz W, Klein BL. Use of activated charcoal in a simulated poisoning with acetaminophen: a new loading dose for N-acetylcysteine? Ann Emerg Med, 22, 1398-1402 (1993).
92) Spiller HA, Krenzelok EP, Grande GA, Safir EF, Diamond JJ. A Prospective Evaluation of the Effect of Activated-Charcoal before Oral N-Acetylcysteine in Acetaminophen Overdose. Annals of Emergency Medicine, 23, 519-523 (1994).
93) Spiller HA, Sawyer TS. Impact of activated charcoal after acute acetaminophen overdoses treated with N-acetylcysteine. J Emerg Med, 33, 141-144 (2007).
94) Inc. CP. Acetadote package insert. (2019).
95) Borgstrom L, Kagedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos, 11, 131-136 (1990).
96) Gorospe EC, Gerstenberger SL. Atypical sources of childhood lead poisoning in the United States: a systematic review from 1966-2006. Clin Toxicol (Phila), 46, 728-737 (2008).
97) Truven Health Analytics Inc.. Poisindex® ''Lead''.
98) Death of a child after ingestion of a metallic charm -Minnesota, Morb. Mortal. Wkly. Rep., 55, 341-342 (2006).
99) Centers for Disease Control and Prevention (CDC). Advisory Committee on Childhood Lead Poisoning Prevention: Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention. Atlanta, GA, (2012)
100) 厚生労働省. 食品衛生法 食品、添加物等の規格基準 第 4 おもちゃ 厚生省告示第３ ７０号 (昭和３４年１２月２８日).
101) ‘‘Safety of Toys—Part 3: Migration of Certain Elements.’’ ISO 8124—3: 2010 (E),(2010).
102) 厚生労働省. 鉛含有金属製アクセサリー類等の安全対策に関する検討会報告書 (2007).
103) 国民生活センター. 子どもが使用することのあるアクセサリーに関する調査結果 －カドミウム、鉛の溶出について－ (2011).
104) 独立行政法人造幣局. ""現在造幣している貨幣."" https://www.mint.go.jp/operations/production/production_kahei/operations_coin_pre sently-minted.html (閲覧日 2020 年 1 月 20 日)
105) 日本イオン交換学会. 図解 最先端イオン交換技術のすべて :焼酎からスーパーカミオカンデまで, 工業調査会, 東京 (2009).
106) 本田 義輝, 中野 真汎, 中野 尚美. 陽イオン交換樹脂および活性炭によるパラコート吸着に及ぼす塩類の影響. 病院薬学, 18, 100-105 (1992).
107) 藤原 邦彦, 工藤 賢三, 池田 実. コレスチラミン投与により血漿中ジゴキシン濃度が迅速に低下したジゴキシン(DGX)中毒症例. 岩手医学雑誌, 45, 351-355 (1993).
108) 山辺 武郎. イオン交換樹脂 : 基礎と応用, 金原出版, 東京 (1962).
109) 興和株式会社. カリメート散 インタビューフォーム 第 13 版 (2016 年 3 月).
110) Watling SM, Gehrke JC, Gehrke CW, Zumwalt R, Pribble J. In vitro binding of lithium using the cation exchange resin sodium polystyrene sulfonate. Am J Emerg Med, 13, 294-296 (1995).
111) Linakis JG, Lacouture PG, Eisenberg MS, Maher TJ, Lewander WJ, Driscoll JL, Woolf AD. Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model. Pharmacol Toxicol, 65, 387-389 (1989).
112) Gehrke JC, Watling SM, Gehrke CW, Zumwalt R. In-vivo binding of lithium using the cation exchange resin sodium polystyrene sulfonate. Am J Emerg Med, 14, 37- 38 (1996).
113) O'Connor TA, Gruner BA, Gehrke JC, Watling SM, Gehrke CW. In vitro binding of iron with the cation-exchange resin sodium polystyrene sulfonate. Ann Emerg Med, 28, 504-507 (1996).
114) Jamshidzadeh A, Vahedi F, Farshad O, Seradj H, Najibi A, Dehghanzadeh G. Amitriptyline, clomipramine, and doxepin adsorption onto sodium polystyrene sulfonate. Daru, 22, 21 (2014).
論文の公開元へ
